Cost Savings With Intramuscular Anticholinergics
J Clin Psychiatry 2001;62:295 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: With the advent of atypical antipsychotics, novel anticonvulsant agents, and selective serotonin reuptake inhibitors, the pharmacotherapy of psychiatric disorders has changed tremendously in the last decade. Although these newer medications are generally better tolerated, and, in some cases, lessen associated costs of more frequent hospitalizations, they have greatly impacted hospital pharmacy budgets. With few of these newer medications available generically, there is little opportunity to decrease medication costs except in interventions such as tablet splitting.